Legend Biotech Downgraded Amid Market Optimism for FDA Guidance
Legend Biotech Corp's stock fell 6.53% and hit a 52-week low, closing at $20.76.
The downgrade from TD Cowen analyst Yaron Werber to Hold, with a reduced price target of $21, reflects concerns about the company's market performance despite recent positive FDA guidance that could benefit its therapies. The FDA's draft guidance allows for new endpoints in multiple myeloma treatments, which analysts believe could enhance Legend Biotech's prospects, especially with its partnership with Johnson & Johnson on the Carvykti cell therapy.
This downgrade comes in a context where the broader market is showing strength, with the Nasdaq-100 and S&P 500 both up, indicating a potential sector rotation affecting Legend Biotech's stock performance.
Trade with 70% Backtested Accuracy
Analyst Views on LEGN
About LEGN
About the author
Legend Biotech (LEGN) Q4 2025 Earnings Transcript
Legend Biotech (LEGN) Q4 2024 Earnings Transcript
Legend Biotech (LEGN) Q2 2025 Earnings Transcript
Legend Biotech (LEGN) Q1 2025 Earnings Transcript
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
Legend Biotech (LEGN) Q4 2025 Earnings Transcript
Legend Biotech (LEGN) Q4 2024 Earnings Transcript
Legend Biotech (LEGN) Q2 2025 Earnings Transcript
Legend Biotech (LEGN) Q1 2025 Earnings Transcript
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
Johnson & Johnson's Holdings Report: The company has restated its fourth-quarter holdings report, which was filed last week.
Exit from Biotechs: Johnson & Johnson has exited three biotech companies as part of its portfolio adjustments.
Retention of Stakes: Despite the exits, the company has retained its stakes in several rumored acquisition targets.
Strategic Moves: These actions indicate a strategic shift in Johnson & Johnson's investment approach within the biotech sector.
EEMA Stock Price Fluctuation and ETF Dynamics
- Price Range Analysis: EEMA's 52-week low is $63.50 per share, with a high of $107.9984, and the latest trade at $96.12 indicates significant price fluctuations that may influence investor buying decisions.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in trend assessment and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) operate similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows or outflows, allowing investors to assess the impact on underlying assets and make informed investment decisions.
